Figure 3.
A. Kaplan-Meier analysis of cancer-specific survival at two years for patients with locoregional pancreatic adenocarcinoma and EUS. EUS group had improved survival (25.4% vs. 16.4%, p<.0001).
B. Kaplan-Meier analysis of non-cancer survival at two years for patients with locoregional pancreatic adenocarcinoma and EUS. EUS group had improved survival (85.3% vs. 78.4%, p<.0001)